bioRxiv · 10.1101/2021.02.01.429199
In vitro evolution of Remdesivir resistance reveals genome plasticity of SARS-CoV-2
Abstract
Remdesivir (RDV) is used widely for COVID-19 patients despite varying results in recent clinical trials. Here, we show how serially passaging SARS-CoV-2 in vitro in the presence of RDV selected for drug-resistant viral populations. We determined that the E802D mutation in the RNA-dependent RNA polymerase was sufficient to confer decreased RDV sensitivity without affecting viral fitness. Analysis of more than 200,000 sequences of globally circulating SARS-CoV-2 variants show no evidence of widespread transmission of RDV-resistant mutants. Surprisingly, we also observed changes in the Spike (i.e., H69 E484, N501, H655) corresponding to mutations identified in emerging SARS-CoV-2 variants indicating that they can arise in vitro in the absence of immune selection. This study illustrates SARS-CoV-2 genome plasticity and offers new perspectives on surveillance of viral variants. One Sentence SummarySARS-CoV-2 drug resistance & genome plasticity
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Szemiel, A. M., Merits, A., Orton, R. J., MacLean, O., Wickenhagen, A., Lieber, G., Pinto, R. M., Turnbull, M. L., Wang, S., Mair, D., da Silva Filipe, A., Willett, B. J., Wilson, S. J., Patel, A. H., Thomson, E. C., Palmarini, M., Kohl, A., Stewart, M. E.. 2021-02-10. In vitro evolution of Remdesivir resistance reveals genome plasticity of SARS-CoV-2. https://doi.org/10.1101/2021.02.01.429199
Cite the original work for its findings. Save a collection to share your selection of sources.